大腸癌多藥耐藥逆轉(zhuǎn)的研究進(jìn)展doc-資料下載頁
2025-07-18 01:37本頁面
【正文】 848. [31] Wiechen K, Zimmer C, Dietel M. Selection of a high activity cerbB2 ribosyme using a fusion gene of a fusion gene of cerbB2 and the enhanced green fluorescent protrin[J]. Cancer Gene Ther, 1998,5(1):4551. [32] Suzuki T, Anderegg B, Ohkawa T, et al. Adenovirus mediated ribozyme argeting of HER2/neu inhibits in vivo growth of breast cancer cells[J]. Gene Ther, 2000,7(3):2418. [33] 陳瑤，[J]. 細(xì)胞生物學(xué)雜志，2003，25(2)：9497. [34] Wagner KW, Nishikura K. Cell cycle expression of RNA duplex unwinding activity in cells[J]. Mol Cell Biol, 1988,8(2):770. [35] Antony T, Thomas T, Shirahata A, et al. Selectivity of polyamines on the stability of RNADNA hybrids containing phosphodie5ter and phosphorothicate o1igodeoxyribonuc1eotides[J]. Biochemistry, 1999,38(33):10775. [36] Fakhrai H, Dorigo O, Shawler DL, et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy[J]. Proc Natl Acad Sci USA, 1996,93(7):L2909. [37] 李玲，徐曼，[J]. 重慶醫(yī)科大學(xué)學(xué)報(bào)，2008，33(6)：686690. [38] 羅華友，揚(yáng)家印，劉自明，[J]. 中華肝臟病雜志，2004，12(2)：8587. [39] Elbashir SM, Harbotth J, LendeckelW, et al. Duplexes of 21 nucleotide RNAs mediate RNA interfefence in cultured mammalian cells[J]. Nature, 2001,411(836):494498. [40] Bass BL. Duplexes of 21nucleotide RNAs mediate RNA interference in cultured mammalian cells[J]. Nature, 2001,411(6836):428429. [41] 袁保梅，[J]. 山東醫(yī)藥，2008，48(26)：1214. [42] 夏忠勝，[J]. 中國病理生理雜志，2009，25(5)：898903. [43] 陳剛，、5氟尿嘧啶聯(lián)合多藥耐藥基因反義RNA對耐藥直腸癌細(xì)胞殺傷作用的研究[J]. 中華外科雜志，2006，44(11)：770773. [44] Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo characterization of XR1 1576，a novel，orally active，dual inhibitor of topoisomerase I and Ⅱ[J]. Anticancer Drugs, 2002,l3(1):l528. [45] 馬強(qiáng)，[J]. 世界華人消化雜志，2001，9(7)：822824. [46] Beck JF, Brugger D, Brischwein K, et al. Anticancer drugmediated induction of multidrug resistanceassociated genes and protein kinase C isozymes in the Tlymphoblastoid cell line CCRFCEM and in blasts from patients with acute lymphoblastic lcukemias[J]. Jpn J Cancer Res, 2001,92(8):896903. [47] Gupta S, Patel K, Singh H, et al. Effect of Calphostin C(PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via Pglycoprotein[J]. Cancer Lett, 1994,76(23):139145. [48] 馬強(qiáng)，[J]. 腫瘤，2002，22(4)：303304. [49] [J]. 廣州醫(yī)學(xué)院學(xué)報(bào)，2008，36(4):6064. [50] 歐陽兵，季旭明，[J]. 山東中醫(yī)藥大學(xué)學(xué)報(bào)，2002，26(6)：472473. [51] 陳育忠，方詠，賈海升，[J]. 新中醫(yī)，2005，37(9)：9293. 申明：本論文版權(quán)歸原刊發(fā)雜志社所有，我們轉(zhuǎn)載的目的是用于學(xué)術(shù)交流與討論，僅供參考不構(gòu)成任何學(xué)術(shù)建議。7 / 7
環(huán)評公示相關(guān)推薦
鄂ICP備17016276號-1